Published in Schizophr Bull on August 11, 2006
Crisis intervention for people with severe mental illnesses. Cochrane Database Syst Rev (2012) 2.23
Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev (2011) 1.49
Fluphenazine (oral) versus placebo for schizophrenia. Cochrane Database Syst Rev (2013) 1.43
The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull (2008) 0.79
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev (2012) 0.75
Social skills programmes for schizophrenia. Cochrane Database Syst Rev (2011) 0.75
Incorporating clinical guidelines through clinician decision-making. Implement Sci (2008) 0.75
Cochrane Schizophrenia Group. Schizophr Bull (2008) 0.75
Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev (2011) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ (2000) 6.67
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry (2004) 6.05
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA (2003) 5.19
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry (1997) 5.03
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res (1999) 4.13
A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry (2003) 3.77
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry (2006) 3.35
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (1996) 2.75
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry (2003) 2.43
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry (2002) 2.41
Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology (2003) 1.96
Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry (2006) 1.66
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol (1997) 1.28
Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull (1999) 1.22
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv (2005) 1.07
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry (2000) 1.03
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol (2000) 1.03
Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) (1998) 0.96
Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand (1998) 0.94
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) (1997) 0.93
One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry (1997) 0.89
Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study. Pharmacopsychiatry (1990) 0.82
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2008) 10.20
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (2013) 8.20
Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet (2007) 7.85
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet (2012) 4.59
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry (2012) 3.29
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry (2003) 3.18
n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr (2010) 3.09
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry (2006) 3.01
What does the PANSS mean? Schizophr Res (2005) 2.86
Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry (2012) 2.61
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry (2008) 2.53
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull (2010) 2.50
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry (2002) 2.41
The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum (2007) 2.25
Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol (2008) 2.02
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum (2011) 1.91
Decoding the massive genome of loblolly pine using haploid DNA and novel assembly strategies. Genome Biol (2014) 1.90
Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry (2012) 1.85
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) (2005) 1.82
The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol (2011) 1.82
The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology (2006) 1.79
Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum (2007) 1.76
Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry (2007) 1.75
The choice of drugs for schizophrenia. N Engl J Med (2006) 1.75
In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci U S A (2005) 1.72
Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology (2006) 1.66
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry (2002) 1.55
Evolution of genome size and complexity in Pinus. PLoS One (2009) 1.52
The use of depot medications in the treatment of schizophrenia. Am J Psychiatry (2010) 1.43
Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin Psychiatry (2010) 1.41
Priming defense genes and metabolites in hybrid poplar by the green leaf volatile cis-3-hexenyl acetate. New Phytol (2008) 1.40
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev (2014) 1.38
Aberrant dependence of default mode/central executive network interactions on anterior insular salience network activity in schizophrenia. Schizophr Bull (2013) 1.35
Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res (2007) 1.34
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology (2007) 1.34
Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2013) 1.30
Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev (2012) 1.29
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry (2002) 1.28
Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology (2012) 1.21
S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. Neuroreport (2007) 1.17
High levels of depressive symptoms in pregnancy with low omega-3 fatty acid intake from fish. Epidemiology (2009) 1.16
Rheumatoid arthritis and cardiovascular disease. Am Heart J (2013) 1.14
Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses (2012) 1.12
Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. Biol Psychiatry (2010) 1.11
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res (2009) 1.11
Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull (2014) 1.11
Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry (2004) 1.08
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol (2007) 1.07
Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data. Arch Clin Neuropsychol (2005) 1.06
Aberrant topology of striatum's connectivity is associated with the number of episodes in depression. Brain (2013) 1.04
Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol (2010) 1.04
Transcript profiles of the cytokinin response regulator gene family in Populus imply diverse roles in plant development. New Phytol (2007) 1.03
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry (2002) 1.03
Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. J Clin Psychiatry (2006) 1.02
Performance of a self-report measure of the level of response to alcohol in 12- to 13-year-old adolescents. J Stud Alcohol (2005) 1.02
Increased intrinsic brain activity in the striatum reflects symptom dimensions in schizophrenia. Schizophr Bull (2012) 1.02
The cytokinin type-B response regulator PtRR13 is a negative regulator of adventitious root development in Populus. Plant Physiol (2009) 1.02
Psychoeducation in schizophrenia--results of a survey of all psychiatric institutions in Germany, Austria, and Switzerland. Schizophr Bull (2006) 1.01
Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis (2010) 1.01
Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depress Anxiety (2009) 1.01
Association mapping of quantitative disease resistance in a natural population of loblolly pine (Pinus taeda L.). Genetics (2010) 1.00
Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids (2009) 1.00
MicroRNA expression in rat brain exposed to repeated inescapable shock: differential alterations in learned helplessness vs. non-learned helplessness. Int J Neuropsychopharmacol (2011) 1.00
Insular Dysfunction Reflects Altered Between-Network Connectivity and Severity of Negative Symptoms in Schizophrenia during Psychotic Remission. Front Hum Neurosci (2013) 1.00
Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep (2010) 1.00
Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol (2011) 0.99
Whole-exome targeted sequencing of the uncharacterized pine genome. Plant J (2013) 0.99
Hippocampal function during associative learning in patients with posttraumatic stress disorder. J Psychiatr Res (2008) 0.99
Reelin down-regulation in mice and psychosis endophenotypes. Neurosci Biobehav Rev (2006) 0.99
Nonflowering plants possess a unique folate-dependent phenylalanine hydroxylase that is localized in chloroplasts. Plant Cell (2010) 0.99
The performance of elements of a 'level of response to alcohol'-based model of drinking behaviors in 13-year-olds. Addiction (2008) 0.98
Lower number of cerebellar Purkinje neurons in psychosis is associated with reduced reelin expression. Proc Natl Acad Sci U S A (2010) 0.97
Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci (2005) 0.97
Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. Psychophysiology (2002) 0.96
Genetic dissection of fusiform rust and pitch canker disease traits in loblolly pine. Theor Appl Genet (2005) 0.95
Methodological factors influencing measurement and processing of plasma reelin in humans. BMC Biochem (2003) 0.95
Testing a level of response to alcohol-based model of heavy drinking and alcohol problems in 1,905 17-year-olds. Alcohol Clin Exp Res (2011) 0.95
Evolution and diversity of invertase genes in Populus trichocarpa. Planta (2007) 0.94
Cognitive functioning in euthymic bipolar I and bipolar II patients. Bipolar Disord (2008) 0.94
Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol (2003) 0.94
First- and second-generation antipsychotics: learning from CUtLASS and CATIE. Arch Gen Psychiatry (2007) 0.94
Aberrant intrinsic connectivity of hippocampus and amygdala overlap in the fronto-insular and dorsomedial-prefrontal cortex in major depressive disorder. Front Hum Neurosci (2013) 0.94
Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective study. J Clin Psychopharmacol (2003) 0.93
Comparative analysis of the transcriptomes of Populus trichocarpa and Arabidopsis thaliana suggests extensive evolution of gene expression regulation in angiosperms. New Phytol (2008) 0.92
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci (2007) 0.92
Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2004) 0.92
The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull (2002) 0.92
Neurobiological underpinnings of shame and guilt: a pilot fMRI study. Soc Cogn Affect Neurosci (2012) 0.92
An evaluation of the performance of the self-rating of the effects of alcohol questionnaire in 12- and 35-year-old subjects. J Stud Alcohol (2006) 0.91
Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull (2008) 0.91
A high-density gene map of loblolly pine (Pinus taeda L.) based on exome sequence capture genotyping. G3 (Bethesda) (2014) 0.91
Efficiency of gene silencing in Arabidopsis: direct inverted repeats vs. transitive RNAi vectors. Plant Biotechnol J (2007) 0.90